Ask the Experts
Dr. Asma Patel is VP of Integrated Development Services at Quotient Sciences. In this role, Asma is responsible for providing scientific and technical support to Quotient Sciences' business development group and leading the consequent design of pharmaceutical science programs.
With over 20 years of experience in pre-formulation and formulation in academia, industry, and contract manufacturing organizations, Asma's expertise covers a wide range of dosage forms, including oral modified-release delivery and formulation strategies to improve the oral delivery of poorly soluble compounds.
Asma received a PhD in pre-formulation and formulation of novel anticancer prodrugs and a Bachelor of Science in Pharmaceutical Sciences, both from De Montfort University.
Additive manufacturing (also known as 3D printing) is now commonplace in many industries. However, for pharmaceuticals, it is still nascent and arguably balancing on the cusp of translation from academic research into industry practice. We do have regulatory validation with SPRITAM®, the FDA-approved commercial product launched by Aprecia in 2015. What will the future impact of 3D printing be for the pharmaceutical industry given the changing dynamics in clinical research?